Biotech/ Pharma Stocks Articles, Commentary and Sector Alerts
Pharma Stock CASI Pharmaceuticals (CASI) Receives U.S. Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma
ROCKVILLE, MD - July 9, 2014 (Investorideas.com Newswire) CASI Pharmaceuticals, Inc. (CASI), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC).
Fire Up the Immuno-Oncology Powerhouses: John McCamant
June 19, 2014 (Investorideas.com Newswire) Forecasting when we'll have a cure for cancer remains beyond the predictive powers of researchers and investors.
Medical Technology News: Medical Technology The Role of Aethlon Medical (OTCQB: AEMD) in the Emerging Immuno-Oncology Market; Q&A with Aethlon Chairman and CEO, Jim Joyce
Point Roberts, WA, NEW YORK, NY - June 10, 2014 (Investorideas.com newswire) Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a Q&A interview with Mr. James A. Joyce ,Chairman and CEO of Aethlon Medical, Inc. (OTCBB:AEMD).
ASCO Abuzz About Immunotherapies: A Preview of the Latest in Cancer Therapy from Stephen Dunn
May 29, 2014 (Investorideas.com Newswire) Working in what is arguably the hottest sector in the drug development industry, biotech researchers continue to ferret out cancer's secrets.
Turn Solid Gold into Biotech Gold with James West
May 29, 2014 (Investorideas.com Newswire) The globe-trotting editor and publisher of The Midas Letter has decided to give his metal investments a breather, looking for new prospects in the life sciences space.
Harnessing the Power of Nature's Perfect Cells: Robert J. Hariri
May 23, 2014 (Investorideas.com Newswire) Neurosurgeon and serial entrepreneur Robert J. Hariri, founder, chairman and chief science officer at Celgene Cellular Therapeutics, describes how his businesses address some of the great unmet needs in medicine in this interview with The Life Sciences Report.
Live Longer, Get Richer with Patrick Cox
May 8, 2014 (www.investorideas.com newswire) It's what every biotech investor dreams of: Transformational advances in healthcare technologies that allow us to live for centuries and accumulate wealth exponentially.
X-Ray Vision or Due Diligence? How SeeThruEquity Analysts Find Hidden Small-Cap Biotech Plays
May 2, 2014 (Investorideas.com Newswire) SeeThruEquity stays an arm's length away from the small biotech firms it analyzes for investors, but gets intimate enough to discover firms that hold promise.
New Melanoma Therapies Are Ready for Primetime: Sanjiv Agarwala
April 30, 2014 (Investorideas.com Newswire) Melanoma confronts patients and their physicians with unique barriers to treatment and successful outcomes.
Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases
April 22, 2014 (Investorideas.com Newswire) To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and sellside analyst.
TSX Biotech Stocks to Watch; Innovative Ovarian Cancer Treatments
New York, NY - Point Roberts, WA - March 26, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source for leading sectors including biotech and pharma issues a sector snapshot of TSX biotech stocks targeting ovarian cancer as part of their product pipeline.
Biopharma IPO alert: Versartis, Inc., (Nasdaq:VSAR) Soars
New York, NY - Point Roberts, WA - March 21, 2014 (Investorideas.com Newswire) Investorideas.com, a global financial and business news source covering leading sectors including biotech issues an IPO alert for Versartis, Inc., (Nasdaq:VSAR) an endocrine-focused biopharmaceutical company.
IPO Alert: Akebia Therapeutics, Inc. (AKBA) Surges in NASDAQ Market Debut
New York, NY - Point Roberts, WA - March 20, 2014 (Investorideas.com Newswire) Investorideas.com, a global financial and business news source covering leading sectors including biotech, issues an IPO alert on Akebia Therapeutics, Inc. (AKBA).
Promising Biotechs Target New Ways to Kill Bad Bugs: Venture Capitalist Dennis Purcell
March 18, 2014 (Investorideas.com Newswire) Dennis Purcell, senior managing partner of Aisling Capital, has seen the biotechnology industry morph from exciting science project to a full-blown, multibillion-dollar industry producing blockbuster products that routinely save lives.
Biotech/Pharma Companies Targeting Pancreatic Cancer: (SBFM), (NLNK), (LLY, NYSE), (CELG)
Point Roberts, WA, New York, NY - February 26, 2014 (Investorideas.com Biotech Newswire) Investorideas.com global news source covering leading sectors including biotech and pharma reports on companies in the sector targeting pancreatic cancer.
Biotech/Pharma Companies Targeting Pancreatic Cancer: (SBFM), (NLNK), (LLY), (CELG)
Point Roberts WA, New York, NY - February 19, 2014 (Investorideas.com Biotech Newswire) Investorideas.com global news source covering leading sectors including biotech and pharma reports on companies in the sector targeting pancreatic cancer.
Biotech News Alert: SUNSHINE BIOPHARMA (OTCQB: SBFM) BEGINS CONSTRUCTION OF MOUSE XENOGRAFT MODELS FOR PANCREATIC CANCER TO ADVANCE Adva-27a AS A TREATMENT FOR THIS DEADLY FORM OF CANCER
Montreal, Quebec, Canada - February 14, 2014 (Investorideas.com Biotech Newswire) Biopharma alert: Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer.
Two Companies Follow Unmet Needs to Biotech Profits: Echo He
January 30, 2014 (Investorideas.com Newswire) Disease progression and drug resistance mean that very sick patients ultimately run out of options.
TSX Biotech Stock: Q&A Interview with CEO of Quest PharmaTech (TSX.V: QPT)
New York NY - Point Roberts WA - January 21, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source for leading sectors including biotech and pharma issues an exclusive interview with Dr. Madi R. Madiyalakan, Ph.D., Chief Executive Officer of Quest PharmaTech Inc. (TSX.V: QPT).
Biopharma Stock Cell Therapeutics (CTIC) Weekly Snapshot
Point Roberts, WA, New York, NY - January 17, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source and resource base for investors following leading sectors including biotech and pharma reports on market activity and recent news for Cell Therapeutics, Inc (CTIC).
Biotech Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust
January 16, 2014 (Investorideas.com Newswire) 2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The 2013 Biotech Watchlist reflected this robustness, boasting a year-to-date return that blew past those posted by the major indices.
Sorting Through the Chaff: The Michael J. Fox Foundation's Tracey Mumford on the Quest to Cure Parkinson's Disease
January 9, 2014 (Investorideas.com Newswire) The business of drug development survives by saving lives, but sometimes nonprofit, private activism is needed to kick-start a new medicine into development.
Micro-Cap Medtech with Explosive Upside Potential: Brian Marckx
December 20, 2013 (www.investorideas.com newswire) Combine the complexity of genomic testing with the high risk inherent in micro-cap stocks, and you have investment opportunities that require exceptional diligence.
Biopharma Q&A Interview; Dr. Steve N. Slilaty Ph.D., Chairman, CEO of Sunshine Biopharma (OTCQB: SBFM) Shares Insight into Recent Company Move and Updates Lead Cancer Compound Adva-27a
New York, NY, Point Roberts, WA - December 19, 2013 (Investorideas.com Biotech Newswire) Investorideas.com, a research and news portal covering leading sectors, issues an exclusive Q&A interview with Dr. Steve N. Slilaty Ph.D., Chairman and CEO of Sunshine Biopharma Inc. (OTCQB: SBFM).
Exosomes; Nano-Scale Bubbles Creating Waves in Diagnostics and Therapeutics
New York, NY, Point Roberts, WA - December 17, 2013 (Investorideas.com newswire) Investorideas.com, an investor news and research portal issues an exclusive sector snapshot on the rapidly growing exosome market and opportunities with key insight from Enal Razvi, Ph.D, Biotechnology Analyst and Managing Director of SelectBio U.S.
Not Your Father's Diagnostics: Ram Selvaraju on How Molecular Genomics Invigorate the Sector
December 5, 2013 (Investorideas.com Newswire) An old investment principle says the equity upside of diagnostics and tools companies can't hold a candle to that of small biotech drug developers.
Biopharma Stock News Alert: SUNSHINE BIOPHARMA (OTCQB: SBFM) EXPANSION AND FINANCING OPPORTUNITIES FOR Adva-27a CANCER DRUG CANDIDATE: Company to RE-DOMICILE IN CANADA
Montreal, Quebec, Canada - December 4, 2013 (Investorideas.com Biotech Newswire) Sunshine Biopharma Inc. ( OTCQB: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is re-domiciling the Company in Canada for expansion through acquisitions and to gain access to various financing opportunities available to Canadian corporations.
Important Development in Cytori Therapeutics Inc.'s Cell Therapy Technology: Joseph Pantginis
November 20, 2013 (Investorideas.com Newswire) Joseph Pantginis: Cytori Therapeutics Inc. is an interesting company right now. It has had a lot of ups and downs over the last several years.
Global Expansion and Affordable Care Act Boost Life Science Tools and Diagnostics: Bryan Brokmeier
November 7, 2013 (Investorideas.com Newswire) Two years ago, medtech was thought to be waning. Investors were deserting companies perceived to be short on margins and sure to be demolished by the Affordable Care Act.
Six Opportunities in the Specialty Pharmaceutical Space: Scott Henry
November 7, 2013 (Investorideas.com Newswire) The specialty pharmaceuticals universe encompasses a variety of technologies, among them innovative drug delivery systems and unique pain management and orphan disease treatments.
Medical Technology Q&A with Chairman and CEO of Aethlon Medical (OTCQB: AEMD) Discussing Launch of New Subsidiary, Exosome Sciences, Inc.
Point Roberts, WA, New York, NY - September 24, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues an exclusive Q&A with Jim Joyce, Chairman and CEO of Aethlon Medical, Inc. (OTCQB:AEMD).
Pharma Stock Alert: Isis Pharmaceuticals (ISIS) Gains on Collaboration News
New York, NY, Point Roberts,WA - September 9, 2013 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research for independent investors including biotech and pharma stocks issues an alert for Biogen Idec (BIIB) and Isis Pharmaceuticals, Inc. (ISIS) following news today of a strategic collaboration to advance treatment of neurological disorders.
BioPharma Stock Alert: Amgen (AMGN) Spikes on News of Acquiring Onyx Pharmaceuticals, Inc. (ONXX)
New York, NY Point Roberts, WA - August 26, 2013 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas for leading sectors including biotech and pharma stocks issues a trading a alert for Amgen Inc. (NasdaqGS: AMGN), trading at $114.88, up $ 9.28 or 8.79% as of 4:29PM on over 7 Million shares.
Three New Picks from the Hot Biotech IPO Market: Ran Nussbaum
August 23, 2013 (www.investorideas.com newswire) Ran Nussbaum, co-founder and managing partner of The Pontifax Group, is a venture capitalist seeking game-changing products that will create real value for patients, pharmas and investors.
Medical Technology Research Alert: Zacks Small Cap Research Update for Aethlon Medical (OTCQB:AEMD); "Remain Encouraged By Ongoing Progress"
Point Roberts, WA, New York, NY - August 20, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues a research alert for Aethlon Medical, Inc. (OTCQB: AEMD).
NASDAQ Top Gainer: BioCryst Pharmaceuticals (BCRX) Continues Run
New York, NY, Point Roberts, WA - July 22, 2013 (www.investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and pharma stocks, issues a trading alert for BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX), trading at $3.57, up $1.11, gaining 45.13% 1:34PM EDT on over 11 Million shares.
Q&A with Chairman & CEO of Aethlon Medical (OTCQB: AEMD) Discussing FDA approval of IDE to Treat Hepatitis C (HCV) Patients and What's Next for the Aethlon Hemopurifier®
Point Roberts, WA, New York, NY - July 9, 2013 (Investorideas.com newswire) Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues an exclusive Q&A with Aethlon Medical, Inc. (OTCQB: AEMD), following recent news that the United States FDA has approved an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier in the United States for the treatment of Hepatitis C virus (HCV).
TSX Biotech Stock Resverlogix Corp. (TSX: RVX) Continues Run
New York, New York - July 3, 2013 (www.investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector research for independent investors issues a trading alert for biotech stock, Resverlogix Corp. (TSX:RVX.TO), continuing its run from yesterday' session where it had gains as high as 152%.
Diagnostics and Stem Cells Power Productive Portfolios: Kevin DeGeeter
June 3, 2013 (Investorideas.com Newswire) New medical tests can be moneymakers for small- and mid-cap companies: They save insurers the pain of paying more to treat maladies and save patients from unnecessary treatments.
New Perspectives and Seven Biotechs for a Diversified Portfolio: Ori Hershkovitz
June 3, 2013 (Investorideas.com Newswire) Sometimes speaking with investors who work half a world away is just what's needed to get a new angle and hear new names. That was the case when we talked with Ori Hershkovitz, managing partner of the Tel Aviv-based Sphera Global Healthcare Fund.
Two Biotech Ideas You May Have Missed: William Gregozeski
May 16, 2013 (Investorideas.com Newswire) Adventurous investors have long sought out micro-cap stocks, attracted by the profit potential of starting on the bottom floor and rocketing toward blue sky.
Biotech, Biopharma Stocks to Watch: (BLGX), (OTC: IGXT; TSX: IGX.V), (SNTS)
Point Roberts, WA - April 30, 2013 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech stocks announces recent biotech and biopharma stocks (OTC:BLGX), (OTC: IGXT; TSX: IGX.V) and (SNTS) added to the biotech stock directory at Investorideas.com.
Biopharma/ Diagnostic Stocks to Watch; (ASTX), (ERB), (MRIC), (ONVO), (SHPG) Recent Additions
Point Roberts, WA - April 29, 2013 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech stocks announces recent biopharma and diagnostic stocks added to the biotech stock directory at Investorideas.com.
TSX and OTC Biotech/ Life Sciences Stocks (TSX.V: SVA), (OTC: APHB), (OTC: BPTH) Added to Investorideas.com Directories
Point Roberts, WA - April 26, 2013 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech stocks releases the following recent TSX and OTC additions to the biotech and life sciences stock directory at Investorideas.com.
TSX and ASX Biotech/ Life Sciences Stocks: (ASX: AHZ), (ASX: AVH), (ASX: CIR), (ASX: IVX), (TSX: AMF) Added to Investorideas.com Directories
Point Roberts, WA - April 26, 2013 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech stocks releases the following recent TSX and ASX additions to the biotech and life sciences stock directory at Investorideas.com.
7 Big Growth Stories in Biotech: Keith Markey
March 28, 2013 (Investorideas.com Newswire) As a former biotechnology researcher and 25-year Wall Street veteran, Griffin Securities Inc. Analyst and Scientific Director Keith Markey understands how novel, cutting-edge technology can produce extraordinary new products that bring in revenues with double-digit growth potential.
Small Companies Are Hubs of Future Profit in Regenerative Medicine: Gil Van Bokkelen
February 28, 2013 (Investorideas.com Newswire) Gil Van Bokkelen has been in the stem cell industry for more than a decade. In recent years, the co-founder, chairman and chief executive officer of Athersys Inc. has stepped into regenerative medicine's forefront, acting as a spokesman for the industry as well as demonstrating his love of science and passionately advocating for patients.
OTC Biotech/ Pharma Stocks Alert: (OTCBB:SBFM), (OTCQB:ONCS), (OTCQB:XXII), (OTCQB:LJPC)
Point Roberts, WA - January 15, 2013 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an alert for investors following stocks in the small and microcap markets.
Josh Levine Names Three Biotech Game-Changers
January 3, 2013 (Investorideas.com Newswire) Micro-cap biotechs must have creative, adaptive management first and foremost, says editor Josh Levine of Josh Levine's MicroCap Investor.
Four Biotech Names with Major Market Potential: Michael Higgins
December 20, 2012 (Investorideas.com Newswire) A bit of luck and a lot of capital: Drug companies need both to navigate the seemingly perpetual path leading to the market debut of a new drug.
Zacks Analyst Jason Napodano's Seven Biotech Picks Will Keep Your Profits on Solid Ground
December 13, 2012 (Investorideas.com Newswire) Low valuation in biotech can be like quicksand under a mirage of low-hanging fruit.
Do You Have the Guts to Take On Cutting-Edge Biotech Like This VC?
December 13, 2012 (Investorideas.com Newswire) With the odds stacked against a drug entering clinical trials, investors need to be assured that the upside will be momentous when success does come.
Can Stem Cells Regenerate Your Portfolio? Stephen Dunn Says Yes
September 27, 2012 (Investorideas.com Newswire) Once the subject of intense political debate, stem cell therapies may soon be a therapeutic mainstay of healthcare.
Stem Cell Stock Alert; Neuralstem (CUR) Gains over 42%
New York, New York - September 13, 2012 (Investorideas.com Newswire) - Investorideas.com, a leader in sector stock research including biotech stocks, issues a trading alert for stem cell stock Neuralstem, Inc. (NYSE MKT : CUR) , trading at $1.42, up $0.42 or 42.00% as of 11:41AM EDT on over 4 Million shares.
Seven Innovative Biotechs That Could Soar by Year-End: George Zavoico
September 13, 2012 (Investorideas.com Newswire) Biotech has a breeze to its back, and successful progression through the phases of drug development also help propel the industry forward.
Chen Lin's Key to Huge Biotech Profits: Make It Personal
August 23, 2012 (www,investorideas.com newswire) Chen Lin is a well-known expert junior metals and energy investor, but he has found compelling reasons to diversify into biotechnology.
Why M&A Flurry Has Top MKM Analyst Smiling All the Way to the Bank
August 16, 2012 (Investorideas.com newswire) Sometimes bigger is better. In this exclusive interview with The Life Sciences Report, Senior Analyst and Managing Director Dr. Jon LeCroy of MKM Partners points to mergers and acquisitions that have bolstered stock prices and singles out biotech and specialty pharma companies
Think Long Term and Win Big with Small Biotechs: Hugh Cleland
August 9, 2012 (Investorideas.com Newswire) - BluMont Capital Portfolio Manager Hugh Cleland has taken a venture capital and private equity approach to investing in public companies, some of which have penny-stock market caps in the $5-15 million range.
Disruptive Biotechnologies Stir Up Profits: Ray Blanco
August 2, 2012 (Investorideas.com newswire) As coeditor of Technology Profits Confidential and contributor to Breakthrough Technology Alert and Penny Sleuth at Agora Financial, Ray Blanco searches far and wide for breakthrough ideas and disruptive technologies that will change the lives of very sick patients.
Sunshine Biopharma, Inc. (OTCBB: SBFM) - Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a
New York, New York - July 30, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues CFA commentary by Patrick J. Murphy of Murphy Analytics LLC on Sunshine Biopharma Inc. (OTCBB: SBFM) and its lead anti-cancer compound, Adva-27a.
Immunotherapies Attack Cancers and Grow Portfolios: Mara Goldstein
July 27, 2012 (Investorideas.com newswire) Sometimes valuations don't match the fundamentals of a stock, according to Cantor Fitzgerald & Co. Senior Biotechnology Analyst Mara Goldstein
Biotech 'Diamonds-in-the-Rough' Promise Huge Potential Returns: Rahul Jasuja
July 19, 2012 (Investorideas.com Newswire, Biotechindustrystocks.com) Rahul Jasuja, managing director and senior biotechnology analyst with Noble Financial Capital Markets, doesn't shy away from the smallest micro-cap companies.
Targeting Aggressive Forms of Cancer: Sunshine Biopharma (OTCBB: SBFM) and Roche (SIX: RO, ROG; OTCQX: RHHBY)
New York, New York - July 9, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a report on biotech companies targeting aggressive forms of cancer; Roche's (SIX: RO, ROG; OTCQX: RHHBY) Herceptin® cancer drug and Sunshine Biopharma Inc. (OTCBB: SBFM) with its lead compound, Adva-27a.
Follow Venture Capital to Big Gains in Biotech: Peter Johann
July 5, 2012 (Investorideas.com Newswire) Peter Johann is a managing general partner at NGN Capital, a venture capital firm that invests in private and public biotech and medical device companies.
Biopharmaceutical Stock Alert: Onyx Pharmaceuticals (NASDAQ: ONXX) Big Moves on FDA Positive Vote
New York, New York - June 21, 2012 (Investorideas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), one of the NASDAQ's top gainers, trading at $62.18, up $17.60 or (39.48%) as of 11:14AM EDT on over 16 Million shares.
Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
SAN DIEGO - June 19, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the U.S. Patent and Trademark Office (USPTO) has given the Company a Notice of Allowance for U.S. Patent Application No. 12/282152 entitled "Extracorporeal Removal of Microvesicular Particles."
Osiris (Nasdaq: OSIR) Receives Second Approval for Life-Saving Stem Cell Drug
Orlando, FL - June 14, 2012 (Investorideas.com Newswire) - The Street Beat commentary - Osiris Therapeutics, Inc. (Nasdaq:OSIR), announced today it has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal (remestemcel-L), for the
Pharma Stocks Dominate NASDAQ Top Percentage Gainers: ARNA, DNDN, HZMP, RPTP
New York, New York - June 13, 2012 (InvestorIdeas.com Newswire) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an alert on the top percentage gainers for morning trading June13th.
Read More
Subscribe to Biotech Stocks News
